Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief...

14
Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information

Transcript of Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief...

Page 1: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Session 1: Responding to Unwarranted Clinical Variation: A Case

Jean-Frederic Levesque

Chief Executive, Bureau of Health Information

Page 2: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Jean-Frederic Levesque, MD, PhDChief Executive

Session 1: Responding to Unwarranted

Clinical Variation – A Case Study

Measuring Stroke Mortality Variation: What We Learned19 June 2014

NSW Health Symposium

Page 3: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

December 5th release: 30-day mortality• Insights into Care report

• Acute myocardial infarction, ischaemic stroke, haemorrhagic stroke, pneumonia, hip fracture surgery

• NSW results and variation within the state

• Hospital profiles

• Up to 21 pages of content for each hospital

• Spotlight on measurement

• Discussion of the approach and sensitivity analyses

• Technical supplement

Page 4: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Why are we reporting this measure?• Mortality following hospitalisation is reported internationally as part of

performance assessments.

• Mortality ratios provide a piece of the picture and are complementary to other quality and safety measures.

• Mortality data is influenced by the performance of local systems, not just hospitals, and of multidisciplinary teams.

• RSMRs are screening tools that provide an indication of where further assessment may be needed.

• Public reporting of mortality results can catalyse improvements in comprehensiveness and appropriateness of care for patients.

Page 5: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

What is this measure about?• It compares the ‘observed’ number of deaths in the 30-days

following admission with the number of ‘expected’ deaths.

• Deaths occurring in-hospital and after discharge are counted using linked data sets.

• A statistical model is used to calculate the ‘expected’ number of deaths based on the age, sex and comorbidities of patients.

• Cases are attributed to their first presenting hospital during an episode of care.

• The findings are not appropriate for comparing or ranking hospitals or for identifying avoidable deaths.

Page 6: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Overview of the results

Page 7: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Overview of the results

Page 8: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Funnel plot Ischaemic Stroke

(∆) Patients are assigned to the first admitting hospital in their last period of care. Data for hospitals with an expected mortality of < 1 are supressed.

(μ) Hospitals with < 50 patients are not reported publicly. Deaths are from all causes, in or out of hospital. Data exclude AMI STEMI-not specified (ICD-10-AM I21.9).

Source: SAPHaRI, Centre for Epidemiology and Evidence NSW Ministry of Health.

Ischaemic stroke 30-day risk-standardised mortality ratio, NSW public hospitals, July 2009 – June 2012 ∆ μ

Page 9: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Analysis by peer group Ischaemic strokeIschaemic stroke 30-day risk-standardised mortality ratio, by peer group July 2009 – June 2012

Page 10: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Hospital profile: Summary dashboard

Page 11: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Hospital profile: Stability of results

Page 12: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Following the report’s release

• Various hospitals have considered the results and identified where improvements could be made.

• Results were reviewed alongside other quality and safety measures, such as clinical audit and review panels.

• Eight clinical settings contacted us to obtain clarifications on the measures or more detailed information.

• Future provision of updates and complementary analyses will be provided.

Page 13: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

What have we learned?• Mortality is an easily understood outcomes that requires very

sophisticated methods to be reported in a fair way

• Understanding contextual and system-level factors is important in developing mortality measures (e.g. impact of transfers)

• Partnering with clinical leaders supports the development of clinically-relevant measures and the rigorous validation

• Internal and public reporting of information acts in synergy to raise awareness and catalyse assessments

• Outcomes that are sensitive but crucial for patients can be part of the range of measures reported publicly to support accountability and meaningful discussion

Page 14: Session 1: Responding to Unwarranted Clinical Variation: A Case Jean-Frederic Levesque Chief Executive, Bureau of Health Information.

Acknowledgements• Kim Sutherland, Director, System and Thematic Reports,

Bureau of Health Information

• Doug Lincoln, Lead Analyst, Bureau of Health Information

• Sadaf Marashi-Poor, Senior Analyst, Bureau of Health Information

• Kerrin Bleicher, Analyst, Bureau of Health Information

• Sally Prisk, Graphic Designer, Bureau of Health Information

• All BHI staff